Latest news with #ProPhaseLabs
Business Insider
a day ago
- Business
- Business Insider
Why Is ProPhase Labs Stock (PRPH) Up 25% Today?
ProPhase Labs (PRPH) stock took off on Tuesday after the consumer healthcare company announced a patent update. The U.S. Patent and Trademark Office has issued its approval for a patent that covers its biomarker-based systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma. This is a type of cancer that develops in the glandular cells lining the esophagus. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ted Karkus, CEO of ProPhase Labs, said, 'With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart.' BE-Smart is the company's molecular diagnostic, which has achieved a greater than 95% technical success rate in detecting its patented panel of biomarkers. Investors will also note that ProPhase Labs will release its Q2 2025 earnings report tomorrow. Wall Street's estimates are for earnings per share of -15 cents and revenue of $3.55 million. ProPhase Labs has historically missed estimates more times than it has surpassed them. ProPhase Labs Stock Movement Today ProPhase Labs stock was up 26.98% in pre-market trading on Tuesday, following a 9.77% drop yesterday. Traders will also note that the shares have fallen 62.93% year-to-date and 88.6% over the past 12 months. Today's movement came with heavy trading, as some 61 million shares changed hands, compared to a three-month daily average of about 903,000 units. Is ProPhase Labs Stock a Buy, Sell, or Hold? Turning to Wall Street, analysts' coverage of ProPhase Labs is lacking. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates PRPH stock a Neutral (46) with a 50-cent price target, representing a potential 77.49% upside for the shares.
Yahoo
3 days ago
- Business
- Yahoo
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the 'Company' or 'ProPhase'), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's investor website. REGISTER HERE: To ensure smooth connectivity, please access this link using the latest version of Google Chrome. About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Media Relations and Institutional Investor Contact:ProPhase Labs, Retail Investor Relations Contact:Renmark Financial Communications Boidman: jboidman@ (416) 644-2020 or (212) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
21-07-2025
- Business
- Globe and Mail
ProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury Initiative
UNIONDALE, NY, July 21, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the 'Company' or 'ProPhase') a next generation biotech, genomics and consumer products company, today announced that its Board of Directors has unanimously authorized the Company's executive team to explore a potential reverse merger transaction with a digital asset-focused operating company to supplement its existing businesses. The Board has also approved a strategic treasury initiative involving the acquisition and long-term holding of select digital assets, including Bitcoin. This initiative represents management's view that a diversified treasury strategy that includes digital assets may enhance long-term shareholder value. The potential reverse merger transaction the Board authorized management to explore would involve combining with a company that maintains a cryptocurrency-focused treasury management and digital asset strategy. This strategic review reflects the Board's interest in identifying complementary growth opportunities that could enhance long-term shareholder value and broaden the Company's market positioning. 'At a time when digital assets and blockchain-native strategies are gaining broader institutional traction, we believe it is prudent to assess opportunities at the intersection of life sciences and financial innovation,' said Ted Karkus, Chief Executive Officer of ProPhase Labs. 'We look forward to evaluating whether such a transaction could provide a platform for scalable value creation.' CEO Karkus continued 'The beauty of this strategic initiative is that we can potentially create additional shareholder value with a goal of maintaining the vast majority of the value of the existing assets for the existing shareholders. This would include the Crown Medical Collections initiative to collect up to $50 million dollars net to the Company for its outstanding COVID accounts receivable, the Nebula Genomics strategic alternatives initiative, and the commercialization of the BE-Smart ™ Esophageal cancer test.' The Company has not entered into any binding agreement at this time and there can be no assurance that any transaction will occur. Management has been authorized to conduct diligence, engage potential counterparties, and evaluate whether such a transaction would be in the best interests of shareholders. The Company will provide additional updates as material developments occur. About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Forward-Looking Statements Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, our ability to successfully transition into a consumer products company, our newly approved crypto treasury strategy, and the potential reverse merger transaction we are exploring. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, cryptocurrency volatility and regulatory risks, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
Yahoo
07-03-2025
- Business
- Yahoo
ProPhase Labs to Present at the Investor Summit Virtual on March 11
GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) ('ProPhase' or the 'Company'), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year's Investor Summit Virtual on March 11th. Event: Q1 Investor SummitPresentation Time: 1:30 P.M. ET Location: Conference Overview and StructureThe Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market. This quarter's event is focused on MicroCap companies who are undervalued and have a catalyst. Registration for Investors To request free registration, please go to and click the 'Registration' button. About ProPhase Labs ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Media Relations and Institutional Investor Contact:ProPhase Labs, Retail Investor Relations Contact:Renmark Financial CommunicationsJohn Boidman212-812-7680Jboidman@
